2026 Impact Factor
1.7
Released June 2026 · Based on 2025 citation data
↓ 0.4 (-19.1%) vs last year
Metric year 2025
Released
Metric year 2024
| Category | Indexes | Quartile |
|---|---|---|
| MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 |
| ONCOLOGY | SCIE | Q4 |
| PHARMACOLOGY & PHARMACY | SCIE | Q3 |
| RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | SCIE | Q3 |
Cancer Biotherapy and Radiopharmaceuticals's newest impact factor is 1.7, released June 17, 2026 and based on 2025 citation data. The journal is listed as JCR Q3 in this Journal Metrics record.
Use this record to check the journal title, ISSN, JCR quartile, CAS block, publisher details, and similar journals before comparing publication venues.
If you searched for Cancer Biotherapy and Radiopharmaceuticals impact factor, compare this exact title record with the journal homepage and nearby journals in the same field. That helps avoid mixing this journal with a similarly named title, abbreviation, society series, or outdated metric snippet.
This page is designed for exact-title searches such as Cancer Biotherapy and Radiopharmaceuticals impact factor. First confirm that the ISSN and title match this record before using the metric in a journal shortlist or submission decision.
For high-stakes submission decisions, verify the title against the publisher record at the journal homepage, Clarivate's Master Journal List or Journal Citation Reports if you have access, and the context in our methodology. Treat the JCR quartile, article volume, and similar journals as supporting context rather than a single-number publication decision.
Ranked #646 in Oncology by impact factor and #151 among Q3 Oncology journals. This context helps compare Cancer Biotherapy and Radiopharmaceuticals against journals publishing in the same field.
Published 269 papers across the last 5 recorded years with a current impact factor of 1.7.
See if your manuscript fits this journal's recent focus before you commit to a shortlist.